Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

und RG7227 (ITMN-191) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently has submitted in support of its NDA file and plans to submit in support of its MAA filing. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly fol
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014 Registreer nu via  http://bit.ly/ag8Sypm14de ... 20. Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen ... PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der Aegate ... neue profitablen Unternehmensdienstleistungen, die für Apotheken und ...
(Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
(Date:12/15/2014)... -- Investor-Edge has initiated coverage on the following ... and Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... and Novartis AG (NYSE: NVS ). Free research ... . On Friday, December 12, 2014, the NASDAQ ... Average lost 1.79%, to finish the day at 17,280.83, and ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5
... -- Neuropsychiatric Data from Pivotal Trial Presented at Annual ... American Association for Geriatric Psychiatry ... ,Medivation, Inc. (Nasdaq: MDVN ) today announced that ... that behavioral symptoms were,stabilized in patients with mild-to-moderate Alzheimer,s ...
... Laser Technology gives patients new lease on life, ... facial plastic,surgeon is giving hope to patients suffering from ... FX by Lumenis is a fractional laser procedure performed ... procedure, a,high- energy beam of laser light is used ...
Cached Medicine Technology:Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress 2Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress 3Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress 4Miami Plastic Surgeon Offers Hope to Acne Scarred Patients 2
(Date:12/19/2014)... 2014 (HealthDay News) -- The tragic death from "rat-bite fever" ... by the pet rodents, according to a report from the ... is a rare but potentially fatal illness that should be ... when a history of rodent exposure is reported," said a ... Intelligence Service. The case outlined in the report occurred ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... December 17, 2014 Unidesk Corporation ... Medicine (ACOM), which welcomed its inaugural class in ... (VDI) to seamlessly support bring your own device ... teaching – experience. The solution, comprised of ... Dell server and storage infrastructure and ...
(Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
(Date:12/17/2014)... News) -- As gas prices rose in recent years, ... suggests. In times of gas increases, more people ... inexperienced, the researchers explained. They examined data gathered ... highest number of motorcycle registrations in the United States ... The analysis revealed a strong association between rising gas ...
Breaking Medicine News(10 mins):Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
... ,It,s Totally Glam to Go for a Mammogram, and ... Men ,Don,t Wait to Check Your Prostate, DALLAS, ... across Texas are sending a different kind of love note to ... women can send an e-reminder to,schedule important cancer screenings that will ...
... ... ... it has begun shipping the new SILVER SEAL(TM) Washable, Antimicrobial,Keyboard. According ... keyboard to be fully submersible, dishwasher safe,and manufactured from SILVER SEAL(TM) ...
... ARLINGTON, Va., Feb. 12 As health care,continues ... election, The HealthCentral,Network, Inc.,s ( http://www.HealthCentral.com ) interactive ... credible tool for voters to determine,which candidate aligns ... Now, washingtonpost.com has chosen the tool for its ...
... 12 Thanks to the collective spirit,of three ... new event has been added to the 2008 ... Triathlon, and registration,is now open., The Ramblin, ... empowerment of women, bring together women of all ...
... a,leading provider of evidence-based nutraceuticals for eye health, today,announced ... its Scientific,Advisory Board., Dr. Coleman is a Professor ... David Geffen School of Medicine at UCLA as well ... Health. She holds,the Frances and Ray Stark Endowed Chair ...
... Transitions, ... Feb. 12 In an effort to heighten,consumer awareness ... debuting a new print, broadcast and digital integrated advertising,campaign ... TV and in print,and will be supported by the ...
Cached Medicine News:Health News:'His and Hers' Screening Campaign Offers Unique Valentine's Day Message to Increase Cancer Screenings and Promote Health 2Health News:'His and Hers' Screening Campaign Offers Unique Valentine's Day Message to Increase Cancer Screenings and Promote Health 3Health News:Seal Shield Ships New SILVER SEAL(TM) Washable, Antimicrobial Keyboard 2Health News:Healthcentral's Healthcare08 Site, an Interactive Health Care Issues Tool, Featured on washingtonpost.com 2Health News:An Event Added to Celebrate and Empower North Carolina Women 2Health News:ScienceBased Health Appoints Anne L. Coleman, MD, PhD to Scientific Advisory Board 2Health News:Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site 2Health News:Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site 3
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Icefire has ice crystals on the top of a cool blue iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medicine Products: